Machina Capital S.A.S. Purchases New Holdings in Hologic, Inc. (NASDAQ:HOLX)

Machina Capital S.A.S. purchased a new position in shares of Hologic, Inc. (NASDAQ:HOLX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,578 shares of the medical equipment provider’s stock, valued at approximately $558,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. McGuire Investment Group LLC raised its position in shares of Hologic by 278.5% in the fourth quarter. McGuire Investment Group LLC now owns 75,655 shares of the medical equipment provider’s stock valued at $3,109,000 after purchasing an additional 55,668 shares during the period. Teachers Advisors LLC raised its position in shares of Hologic by 9.7% in the third quarter. Teachers Advisors LLC now owns 503,343 shares of the medical equipment provider’s stock valued at $20,627,000 after purchasing an additional 44,640 shares during the period. Assenagon Asset Management S.A. bought a new position in shares of Hologic in the fourth quarter valued at about $5,105,000. Essex Savings Bank bought a new position in shares of Hologic in the fourth quarter valued at about $37,000. Finally, Mesirow Financial Investment Management Equity Management raised its position in shares of Hologic by 19.3% in the fourth quarter. Mesirow Financial Investment Management Equity Management now owns 38,555 shares of the medical equipment provider’s stock valued at $1,585,000 after purchasing an additional 6,240 shares during the period. 89.91% of the stock is currently owned by hedge funds and other institutional investors.

In other Hologic news, insider Peter J. Valenti III sold 4,242 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $47.38, for a total transaction of $200,985.96. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Sally Crawford sold 12,306 shares of the stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $47.61, for a total transaction of $585,888.66. Following the sale, the director now owns 168,886 shares in the company, valued at $8,040,662.46. The disclosure for this sale can be found here. Insiders have sold 23,378 shares of company stock worth $1,105,836 over the last quarter. Corporate insiders own 0.90% of the company’s stock.

Hologic stock traded up $0.47 during trading hours on Wednesday, reaching $44.73. 1,166,276 shares of the stock were exchanged, compared to its average volume of 1,898,432. The company has a market capitalization of $12.59 billion, a price-to-earnings ratio of 20.06, a PEG ratio of 2.04 and a beta of 0.75. The company has a quick ratio of 0.91, a current ratio of 1.30 and a debt-to-equity ratio of 1.18. Hologic, Inc. has a twelve month low of $35.10 and a twelve month high of $48.82.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, January 30th. The medical equipment provider reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.01. The firm had revenue of $830.70 million for the quarter, compared to the consensus estimate of $823.22 million. Hologic had a negative net margin of 12.88% and a positive return on equity of 25.59%. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.55 earnings per share. On average, sell-side analysts expect that Hologic, Inc. will post 2.41 earnings per share for the current year.

Several brokerages have recently weighed in on HOLX. Zacks Investment Research lowered shares of Hologic from a “hold” rating to a “sell” rating in a research report on Wednesday, April 10th. ValuEngine downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research note on Tuesday, April 16th. Finally, BidaskClub downgraded shares of Hologic from a “hold” rating to a “sell” rating in a research note on Tuesday. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $44.62.

WARNING: This piece of content was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/04/24/machina-capital-s-a-s-buys-new-stake-in-hologic-inc-holx.html.

Hologic Company Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Story: Understanding Market Liquidity

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.